Morelli, M. P., Basar, R., Marin, D., Zeller, B. E., Willis, J., Kee, B. K., Jacob, S., Diao, S., Huey, R. W., Morris, V. K., Bent, A. H., Haldar, S. D., Nurmammadova, A., Bohat, R., Menter, D., Overman, M. J., Shen, X., Kopetz, S., Shpall, E. J., Rezvani, K. (2026). Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps275